Test Price
2,800 AED✅ Home Collection Available
DAG1 Gene Muscular Dystrophy-Dystroglycanopathy (Limb-Girdle), Type C9 Genetic Test in UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO-Accredited NGS with Sanger validation.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM).
- Clinical Guidance: Telephonic Post-Test Genetic Counseling by a Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
The DAG1 gene NGS test identifies pathogenic variants causing limb-girdle muscular dystrophy-dystroglycanopathy type C9, a progressive autosomal recessive disorder. This test provides comprehensive coverage of the DAG1 coding region and intron-exon boundaries with robust copy number variant detection, delivering a definitive molecular diagnosis for targeted management and genetic counseling.
| Feature | Our Test (NGS Gold Standard) | Closest Alternative (Sanger Only) |
|---|---|---|
| Precision | 99.9% analytical sensitivity, full gene coverage + copy number detection | Limited to targeted regions, may miss deep intronic variants |
| Methodology | NGS (Next-Generation Sequencing) with orthogonal Sanger confirmation of all clinically significant variants | Sanger sequencing of coding exons only |
| Turnaround Time | 3 to 4 Weeks | 6–8 Weeks |
| Clinical Depth | Interpretation aligned with ACMG/ClinGen guidelines and UAE genetic counseling standards | Basic variant report without comprehensive clinical context |
Physician Insight & Safety Protocols
“As a Consultant Medical Geneticist, I appreciate the diagnostic confidence that comprehensive NGS analysis brings to families navigating limb-girdle muscular dystrophy. This test minimizes the diagnostic odyssey, enabling targeted management and informed family planning. A negative result does not rule out other myopathies, and clinical correlation remains essential.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Clinical Advisory
Do not discontinue or alter prescribed medications without consulting your physician. This test is intended for diagnostic confirmation and does not replace emergency care for acute muscular deterioration.
Exclusion Criteria & ER Red Flags
- Not for emergency diagnosis of acute muscular deterioration.
- Minors below 18 years require a genetic counseling session and legal guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Prenatal/preimplantation use without UAE medical board approval is not permitted.
- Not validated as a stand-alone screening in asymptomatic individuals without a confirmed family mutation.
Seek immediate emergency care if you experience:
- Rapidly worsening muscle weakness or inability to stand.
- Breathing difficulty, choking, or chest pain.
- Loss of consciousness or cardiac arrhythmia.
Patient FAQ & Clinical Guidance
1. What is the DAG1 gene test and why is it performed?
It identifies DAG1 gene mutations responsible for limb-girdle muscular dystrophy type C9, guiding targeted management and genetic counseling. This diagnostic test is recommended for individuals with progressive proximal muscle weakness, elevated CK, and a family history suggestive of dystroglycanopathy. Results enable accurate prognosis assessment, reproductive risk counseling, and enrollment in clinical trials.
2. How is the test performed and what sample is required?
VIP Mobile Phlebotomy collects a blood sample; NGS-based analysis provides results within three to four weeks. A certified phlebotomist visits your home (8 AM – 11 PM) to draw 4 mL of whole blood in an EDTA tube; alternative accepted samples are extracted DNA or a dried blood spot on an FTA card. The sample is transported under cold chain to our ISO 9001:2015 lab for high-depth sequencing.
3. Will my insurance cover this test?
Direct insurance verification via WhatsApp; most UAE plans cover genetic testing for medically indicated cases. We facilitate pre-authorization by liaising with major insurers (Daman, Thiqa, Neuron, etc.) after you send a copy of your referral via +971 54 548 8731. Coverage typically applies when a neurologist or geneticist orders the test and clinical findings support the indication.
UAE Regulatory & Data Privacy Adherence
Your Data, Your Rights
DNA Labs UAE operates under DHA Facility License 1143 and adheres strictly to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of ICT in Health Fields. All genetic data is encrypted, stored securely, and never shared without explicit consent. You have the right to access, rectify, and request deletion of your data, subject to legal retention requirements.
Clinical & Logistical Metadata
| Test Name | DAG1 Gene Muscular Dystrophy-Dystroglycanopathy (Limb-Girdle), Type C9 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Dried Blood Spot (FTA card), or Extracted DNA |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger Confirmation |
| ICD-10-CM Code | G71.0 |
| LOINC Code | 92951-2 |
| DHA Facility License & Address | License 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians